News

Brain Volume, NfL Level Changes May Predict Disability in Relapsing MS

A model that considers changes in brain volume and serum neurofilament (sNfL) levels during the early stages of multiple sclerosis may help clinicians to determine an individual’s likely progression with relapsing forms of MS, a study suggests. “We were able to build reliable, robust models capable of accurate predictions of…

Reprise of ‘DarkHawk’ Marvel Comic Features Superhero With MS

The main character of a new, five-issue reprise of the original “Darkhawk” Marvel comic battles crime while navigating his way through being newly diagnosed with multiple sclerosis (MS). Connor Young, a 17-year-old high school senior and basketball star, has his life turned upside down with this news, when he…

Submissions Now Open for 2022 MSAA Art Showcase

The Multiple Sclerosis Association of America (MSAA) is calling for submissions for its 2022 MSAA Art Showcase, an initiative that celebrates the work of artists who have multiple sclerosis (MS). The showcase, which began in 2009, gives MS patients in the U.S. the opportunity to share their…

Medsenic Being Granted US Patent for Arscimed for RRMS

The U.S. Patent and Trademark Office will grant Medsenic a patent covering the use of Arscimed, its investigational formulation of arsenic trioxide, for the treatment of relapsing-remitting multiple sclerosis (RRMS). Once issued, the patent will protect Arscimed’s use for this indication until 2037. This will add to the already…

Innodem, Novartis Team Up on Trial Testing Eye-tracking Technology

Innodem Neurosciences is teaming up with Novartis Canada on a breakthrough clinical trial to evaluate if Innodem’s digital biomarker eye-tracking technology can monitor disease progression in people with multiple sclerosis (MS). The trial will test Innodem’s “easy-to-use, affordable technology,” which works using visible light, with no special infrared…

Australian Council Supports Research Into MS Risk Factors, Falls

Australia’s National Health and Medical Research Council (NHMRC) is giving a total of AU$6.75 million (about $5 million) in grants to advance research into multiple sclerosis (MS), including risk factors for the disease, preventing falls, and harnessing viral-immune system interactions to improve patients’ lives. The three investigator grants,…

Hydroxychloroquine Shows Potential to Treat PPMS in Phase 2 Trial

Treatment with hydroxychloroquine, an anti-malaria medication, appeared to help slow disability progression among people with primary-progressive multiple sclerosis (PPMS) in a small, proof-of-concept clinical trial. Hydroxychloroquine “is a promising treatment candidate for PPMS and should be investigated further in randomized controlled clinical trials,” its researchers wrote. Results of the study…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here

Video